Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

NCT07104383 · View on ClinicalTrials.gov ↗

Study Summary

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight

Conditions Studied

Interventions

  • DRUG VK2735

Study Locations (20)

California

  • Viking Clinical Site #2071 — Chula Vista
  • Viking Clinical Site #2070 — Escondido
  • Viking Clinical Site #2054 — Huntington Park
  • Viking Clinical Site #2014 — Lake Forest
  • Viking Clinical Site #2129 — Lemon Grove
  • Viking Clinical Site #2051 — Lincoln
  • Viking Clinical Site #2050 — Long Beach
  • Viking Clinical Site #2055 — Los Angeles
  • Viking Clinical Site #2078 — Manteca
  • Viking Clinical Site #2053 — Montclair

Arizona

  • Viking Clinical Site #2005 — Chandler
  • Viking Clinical Site #2017 — Flagstaff
  • Viking Clinical Site #2018 — Peoria
  • Viking Clinical Site #2135 — Scottsdale
  • Viking Clinical Site #2019 — Tucson

Alabama

  • Viking Clinical Site #2037 — Birmingham
  • Viking Clinical Site #2064 — Birmingham
  • Viking Clinical Site #2128 — Huntsville
  • Viking Clinical Site #2081 — Mobile

Arkansas

  • Viking Clinical Site #2036 — Little Rock

Trial Details

FieldValue
Enrollment Target 1,100 participants
Start Date 2025-06-23
Est. Completion 2027-08-01
Phase Phase 3

Sponsor

Viking Therapeutics

4 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07104383

The ClinicalTrials.gov registry entry for NCT07104383 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viking Therapeutics, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Weight Loss appearing as the primary indexed condition, and to 1 intervention — of which VK2735 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07104383 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Arizona, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07104383 about?

NCT07104383 is a clinical study titled "VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)". This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight

What is the current status of trial NCT07104383?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2025-06-23. Estimated completion is 2027-08-01.

What conditions does trial NCT07104383 study?

This clinical trial studies the following conditions: Weight Loss. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07104383?

The interventions under investigation include: VK2735 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07104383?

This trial is sponsored by Viking Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07104383 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial